Linomide (Roquinimex) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity. It also inhibits angiogenesis and reduces the secretion of TNF alpha. Linomide has been investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes. Several trials have been terminated due to serious cardiovascular toxicity.
Synthesis
Ethyl 2-(methylamino)benzoate is condensed with ethyl malonate. Amine-ester interchange of that compound with N-methylaniline results in formation of the amide linomide.
References


![Linomide: Linomide synthesis:[4]](https://upload.wikimedia.org/wikipedia/commons/thumb/8/84/Roquinimex_synthesis.svg/500px-Roquinimex_synthesis.svg.png?utm_source=en.wikipedia.org&utm_campaign=parser&utm_content=thumbnail)
